As of the 23 June 2025, Tirzepatide (Mounjaro®), is available on the NHS for a limited number of patients. Tirzepatide (Mounjaro®) will not be accessible to everyone who wishes to use it. People with the highest health risks and who meet the clinical criteria will be prioritised.
We are currently working with partners to develop a service to support the year one implementation for patients that qualify under the criteria and will update you as soon as this is agreed.
Patients will be eligible for tirzepatide (Mounjaro®) for the management of obesity where a clinician considers it an appropriate treatment and if they have four or more of the following weight related health problems, as well as BMI of 40 and over:
• type 2 diabetes
• high blood pressure
• heart disease
• obstructive sleep apnoea
• abnormal blood fats or dyslipidaemia
It is important to note that only patients who meet the qualifying criteria will be eligible to receive Mounjaro on the NHS for weight loss, and that meeting the criteria does not guarantee access.
If you wish to start Tirzepatide (Mounjaro®), you will also be referred for diet and lifestyle intervention alongside the medication. This is an essential part of your treatment pathway. If you are interested in Mounjaro and believe that you meet, or may meet, the qualifying criteria then please contact your GP practice.
In future years the criteria for access to this medication will be expanded, and we will update this website as this happens.
For those who do not yet meet the criteria for Tirzepatide (Mounjaro®) but who wish to lose weight, there are other resources available. Please refer to the below web pages which list those services currently available to patients, or contact your GP practice:
For further information regarding Tirzepatide (Mounjaro®) and NHS Obesity Services:
